Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.
about
Beneficial effects of nicotine, cotinine and its metabolites as potential agents for Parkinson's diseaseAlpha-Synuclein in Parkinson's Disease: From Pathogenetic Dysfunction to Potential Clinical ApplicationSynthetic Proteins and Peptides for the Direct Interrogation of α-Synuclein Posttranslational ModificationsMechanisms of Parkinson's disease-related proteins in mediating secondary brain damage after cerebral ischemia.Overexpression of the calpain-specific inhibitor calpastatin reduces human alpha-Synuclein processing, aggregation and synaptic impairment in [A30P]αSyn transgenic mice.Analysis of alpha-synuclein in malignant melanoma - development of a SRM quantification assayUnbiased approaches to biomarker discovery in neurodegenerative diseasesProteomics analyses for the global proteins in the brain tissues of different human prion diseases.Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein.Comparison of strategies for non-perturbing labeling of α-synuclein to study amyloidogenesis.Mitochondrial dysfunction and cell death in neurodegenerative diseases through nitroxidative stressActivation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegenerationPoststroke Induction of α-Synuclein Mediates Ischemic Brain Damage.A user's guide for α-synuclein biomarker studies in biological fluids: Perianalytical considerations.Validation of electrochemiluminescence assays for highly sensitive and reproducible quantification of α-synuclein in cerebrospinal fluid.Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.Looking at the recent advances in understanding α-synuclein and its aggregation through the proteoform prism.Phosphorylation Interferes with Maturation of Amyloid-β Fibrillar Structure in the N Terminus.Phosphorylation modifies the molecular stability of β-amyloid deposits.α-synuclein conformational antibodies fused to penetratin are effective in models of Lewy body disease.Alpha-, Beta-, and Gamma-synuclein Quantification in Cerebrospinal Fluid by Multiple Reaction Monitoring Reveals Increased Concentrations in Alzheimer's and Creutzfeldt-Jakob Disease but No Alteration in SynucleinopathiesLabel-Free and Real-Time Detection of Protein Ubiquitination with a Biological NanoporePosttranslational modifications of blood-derived alpha-synuclein as biochemical markers for Parkinson's disease.Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry.Mitochondrial function and autophagy: integrating proteotoxic, redox, and metabolic stress in Parkinson's disease.MS-based methods for biomarkers of Parkinson's disease: what is the future?Altered α-synuclein, parkin, and synphilin isoform levels in multiple system atrophy brains.Exploring the role of post-translational modifications in regulating α-synuclein interactions by studying the effects of phosphorylation on nanobody binding.The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson's disease
P2860
Q21131066-79FDF4CA-470A-47E4-9ED2-0C19A8AE4E8DQ28079911-E853053B-FBA2-4ECA-9858-266703D5B891Q28081548-915F0FA7-0442-4499-8CF4-0D9CC6FD5DDBQ33727623-4C44427D-62F8-470E-BD89-89641AF9B518Q33947949-B8875ABF-ADEA-4AE1-BCAB-3BBCDD08BDEFQ34379982-3EB279FE-31B1-4E1C-A5FF-517B5D81A9B9Q34625918-9A4854B1-5414-45C9-926B-39485F25D9B9Q35325652-6957663A-03E3-487C-9C5C-AF6973AACD31Q36321556-BC56AECE-3448-4DE5-B52B-DFCC04010BF8Q36523637-A321325B-8798-4983-A10E-C9C94769C662Q36767908-5FCE9985-CBDF-4344-A191-0C21A47AFFC7Q37137895-6041A670-10BC-4CB0-969A-6FA869BBF768Q37196992-5CDB64A2-0AC9-4C4A-AE55-EDFAAAECBF8EQ38653383-1DB0AB73-33CA-46A9-9F24-6CFA8D2D3A2BQ38786158-48915070-BF7E-4F97-B8B8-F6C1E4798F86Q38825497-414E26B5-AD4C-45AC-ACFE-2CAE9ABD7D20Q39297100-FC14A82C-6AFE-4462-8FEC-8F642410C031Q39716461-AF6FCDB0-3C6A-4D7A-85C3-35C8750614F9Q40249589-8D1CCE0C-3401-454F-B7FF-328276E66CE6Q41117719-52466D38-0A26-41BA-B162-1BF858EC6586Q41653656-B9F55B9D-A824-475D-8F21-3989BD0AFB5DQ41823057-A88562E2-A8B7-4FE6-BCE2-731996301278Q42653035-9FA3C347-BE1A-4180-B5CC-AE41911CAC74Q47587631-884B6829-5942-400F-A85B-8BDA6A85A8BDQ47653685-3B36EA48-AAF5-4A1F-B86D-BC9724F266E1Q48633515-6C1C3C3C-2BB1-4BFE-A2BB-318AD2BE8867Q52147948-055CF32B-72AE-4B3D-B6EF-DDAB6443FFEEQ53823040-CDBA6998-D9BF-43CD-BC4E-C417E7ABB84BQ58577817-08DBCC64-CA04-4C7C-90B8-7F2AFAF68826
P2860
Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Alpha-synuclein post-translati ...... e and other synucleinopathies.
@en
Alpha-synuclein post-translati ...... e and other synucleinopathies.
@nl
type
label
Alpha-synuclein post-translati ...... e and other synucleinopathies.
@en
Alpha-synuclein post-translati ...... e and other synucleinopathies.
@nl
prefLabel
Alpha-synuclein post-translati ...... e and other synucleinopathies.
@en
Alpha-synuclein post-translati ...... e and other synucleinopathies.
@nl
P2860
P921
P356
P1476
Alpha-synuclein post-translati ...... e and other synucleinopathies.
@en
P2093
Adrien W Schmid
Marc Moniatte
P2860
P304
P356
10.1074/MCP.R113.032730
P577
2013-08-21T00:00:00Z